| |
|
| Source: Company documents |
|
|
| Name
: |
Paul Goddard |
| Title
: |
Chairman and CEO |
| Since: |
|
|
|
|
|
| Name
: |
Peter G. Milner |
| Title
: |
President Research and Development and Director |
| Since: |
|
|
|
|
|
| Name
: |
John Varian |
| Title
: |
COO and CFO |
| Since: |
|
|
|
|
|
|
|
|
| |
|
| Earnings
Release Dates : 13th May 2008 , 12th March 2008 |
|
 Audio |
|
|
| |
|
| |
|
| |
|
| |
| American Public Education Prices Above Range Nov 13, 4:02 PM EST |
|
| |
ARYx Therapeutics
The Company’s most advanced product is ATI-7505, an oral prokinetic drug that has successfully completed Phase 2 clinical trials for the treatment of multiple gastrointestinal disorders including gastroesophageal reflux disease, or GERD, and functional dyspepsia.
ATI-7505 was designed to have the same therapeutic benefits as cisapride, a drug marketed by Johnson & Johnson as Propulsid in the United States.
|
| More... |
|
|
|
